新型瓜尼丁衍生物作为抗癌剂的机械支架:合成,表征,DNA结合和计算研究
Hina Zaman1, Aamer Saeed1, Uzma Azam1
1Department of Chemistry, Quaid-I-Azam University Islamabad 45320 Pakistan asaeed@qau.edu.pk +92-51-9064-2241 +92-51-9064-2128.
RSC advances
|September 4, 2025
概括
新型瓜尼丁衍生物通过选择性地与DNA小沟结合显示出具有前途的抗癌药物. 化合物7i表现出显著的DNA结合 afinity,支持其未来癌症药物开发的潜力.
科学领域:
- 医学化学
- 分子生物学
- 生物物理化学
背景情况:
- 癌症仍然是全球严重的健康问题,
- 向DNA是破坏癌细胞增殖的有效策略.
- 开发具有选择性DNA结合能力的新疗法至关重要.
研究的目的:
- 合成和描述新的瓜尼丁衍生物.
- 调查它们的DNA结合潜力和机制.
- 评估它们作为抗癌药物的适用性.
主要方法:
- 瓜尼丁衍生物的合成和表征 (7a-j).
- 电子吸收光谱测定与鱼精子DNA (SS-DNA) 的DNA结合相互作用.
- 分子对接,DFT计算和ADMET预测用于机械和药物动力学的洞察力.
主要成果:
- 瓜尼丁衍生物呈现低色变化,表明小槽与DNA结合.
- 化合物7i具有较高的结合常数 (Kb = 3. 49 × 10^5 M^-1),与参考药物相当.
- 分子对接显示了化合物7i在DNA小槽中的有利相互作用.
结论:
- 新型瓜尼丁衍生物,特别是化合物7i,具有显著的DNA结合特性.
- 它们的抗癌潜力的机制性基础是DNA小沟结合.
- 这些化合物需要进一步的研究,
相关概念视频
Structure-Activity Relationships and Drug Design
1.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.0K
Drug Discovery: Overview
8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K


